January 5, 2017 08:47 AM EST
Pharma

J&J grabs an op­tion to buy a NASH drug in lat­est string of biotech deals

Arsalan Arif

Founder

J&J has grabbed an op­tion to buy Bird Rock Bio and its ex­per­i­men­tal NASH drug can­di­date, the CB1-tar­get­ing an­ti­body na­ma­cizum­ab, if the phar­ma gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A look at biotech's year of the megaround

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

A service from the Financial Times